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ABSTRCT
ASSESSING THE ROLE OF ARSENITE IN DISRUPTING THE EGFR SIGNALING
AXIS
Christine Kim
August 16, 2018
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase
localized on the cell surface. Overexpression of EGFR has been used as biomarkers for
many different types of cancers, including lung cancer. There is a strong association
between arsenic and lung cancer development, although the mechanism is unclear. We
hypothesize that chronic exposure of “a physiologically relevant” level of arsenite
disrupts the EGFR endocytic trafficking. The goal of this project is to identify
molecular mechanisms and roles of chronic arsenite-induced EGFR overexpression in
lung cancer development. A non-malignant human bronchial epithelial cell line, Beas-2B
cells were exposed to 100 nM sodium arsenite for 24 weeks. The chronic arsenitetreated cells had increased EGFR protein expression levels and activity, increased
transcription levels of TGFα, and altered the distribution of the EGFR. In conclusion, the
impact of chronic arsenite exposure on the EGFR signaling axis can explain arseniteinduced overexpression of the EGFR.
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CHAPTER 1
INTRODUCTION
Arsenic
Environmental contamination of heavy metals is a global health hazard. Among
heavy metals, arsenic is ranked number one on the Agency for Toxic Substances and
Disease Registry (ATSDR) Substance Priority List (ATSDR, 2017), and in 1973, arsenic
was classified as group I “carcinogenic to humans” by the International Agency for
Research on Cancer (IARC) based on epidemiological carcinogenicity evidence in
human and in animal models [1-3]. Arsenic is ubiquitous in the environment, and it has
been used by of human civilization since ancient times, both for constructive and
destructive purposes. Arsenic is a powerful poison, owing to its lack of color, taste and
odor. Moreover, the symptoms from arsenic poisoning are very similar to the symptoms
of food poisoning, thus rendering it nearly untraceable without sophisticated analytical
procedures.
i. Arsenic Uses in Medical Applications
Arsenic is a double-edged sword, as it has been used for medical applications
(Fig. 1). In the 18th century, Thomas Fowler, an English physician, produced Fowler’s
Solution, a potassium bicarbonate-based arsenic solution, which was widely used to
treat many conditions such as asthma, convulsions [4] and psoriasis [5]. Also known as
a cancer of the blood cells, leukemia is associated with abnormally high number of white
blood cells. Arsenic was also used to treat leukemia; with the Fowler’s Solution, the
number of white blood cells declined dramatically in leukemia patients over 10-weeks
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Arsenic: A Double-Edged Sword
Figure 1. Arsenic is a double-edged sword. Arsenic is now a well-established
carcinogen and is prominently associated with skin, lung, and bladder cancers. Arsenic
is also used in medical applications, especially as a treatment for leukemia. Despite its
effectiveness, over time, carcinogenicity was observed in patients who had received
arsenic treatment. Thus, its usage declined, but due to its potency in medical
applications, it is under investigation for the treatment for other diseases.
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treatment period [6]. Discontinuation of the therapy, however, led to clinical relapse
within few weeks. Because of its anti-leukemic ability, arsenic was approved by Food
and Drug Administration (FDA) in 2001 for the treatment of acute promylelocytic
leukemia (APL) [7], and is under investigation for the treatment of other cancer types [810].
Arsenic hinders repair processes of UV-induced photoadducts [11-14], and its
role in repressing DNA repair processes also contributes to chemotherapeutic effect.
Wang et al. showed combination treatment of arsenic with cisplatin is more effective in
treating hepatocellular carcinoma than cisplatin treatment alone [15]. Further, Neher et
al. observed cisplatin treatment alone induces xeroderma pigmentosum group C (XPC),
which is an important protein in the global genomic nucleotide excision repair pathway
[16], suggesting cisplatin-induced XPC expression is a part of the resistance mechanism
in cisplatin-resistant cells. Interestingly, co-treatment of arsenic with cisplatin suppressed
cisplatin-induced XPC expression by sensitizing wild-type p53, inhibiting the repair
pathway [17]. This study highlights the enhanced chemotherapeutic effect of cisplatin
when it is given with arsenic, and suggests a potential role of arsenic in enhancing
sensitivity towards chemotherapeutic agents. Overall, such characteristics of arsenic
support its contribution not only to carcinogenesis, but also to chemotherapy.
Health Effects of Acute and Chronic Arsenic Exposure
Arsenic toxicity is highly dependent on its dose and duration of exposure time, as
its acute toxicities are different from chronic toxicities. Usually acute toxicity results from
accidental ingestion of high levels of arsenic. Ingestion of large amounts of arsenic will
require treatment, such as decontamination, administration of intravenous fluids, and
chelation therapy. The symptoms, including diarrhea, vomiting, dehydration, and
hypotension, are commonly observed in workers who ingest high levels of arsenic in
their workplaces from dust and fumes. In severe cases, the symptoms can lead to death,
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primarily due to dehydration and shock [18]. To determine the acute exposure to arsenic,
several tests can be performed, including blood and urine tests. Blood test, however, is
accurate only for 2-4 hours after initial exposure due to rapid clearance from the blood
[19]. More accurate measurement would be determined by performing urine test.
Twenty-four hour urine arsenic levels greater than 50 µg/L are considered acute arsenic
toxicity [20].
Chronic toxicity is also commonly seen in workers who are exposed to low levels
of arsenic over a long period of time. The skin, lungs, and liver are the main target sites,
as arsenite, especially, readily interacts with thiol or sulfhydryl groups in tissue proteins
of the organs [21]. The reaction between arsenic and thiol groups can hinder critical
biochemical events that lead to major toxicities, and symptoms include skin lesions,
pulmonary disease, hypertension, cardiovascular disease, diabetes, neurological
disorders, cancer, and death [21-23]. Because epithelial cells have high content of
cysteine residues, arsenic tends to accumulate at those locations due to its reactivity
with thiol groups of cysteine residues [24, 25]. Thus, for chronic arsenic exposure,
usually hair and nail analysis are useful to measure the time of exposure. The
concentration of arsenic in hair in individuals who have no known arsenic exposure
ranges from 0.02 to 0.2 mg/kg [26-32]. In areas with high concentrations (>50 µg/L) of
arsenic in drinking water, the arsenic hair level ranges from 3 to 10 mg/kg [33]. Chelation
therapy can be used to mitigate chronic arsenic toxicity, but chronic arsenic exposure
can cause many irreversible changes in organs and tissues. Unfortunately, there is no
effective treatment, which increases mortality rate [34, 35]. It is difficult to deduce
whether acute and chronic toxicities result from two distinct mechanisms, because 1)
different biochemical mechanisms may occur in different tissues and organs, and/or, 2)
different duration time at the same organ may result in different biochemical
mechanisms. Therefore, depending on dose and duration of exposure, arsenic can
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target many different types of tissues and organs, causing adverse health effects [36].
The acute and chronic arsenic toxicological effects on human health are summarized in
Table 1.
Arsenic in Drinking Water
As mentioned above, due to its toxicity and the frequency of human exposure,
arsenic is ranked number one on the ATSDR Substance Priority List, and its
environmental contamination is a global issue. Although the Environmental Protection
Agency (EPA) has set the standard for arsenic in municipal drinking water of 10 ppb
(parts per billion), which is approximately 133 nM, we are still exposed to low levels of
arsenic on a daily basis. Exposure to arsenic is associated with an increased risk for a
variety of health problems, such as skin and nerve damage, and cancer. More than 200
million people worldwide are chronically exposed to drinking water that is contaminated
with arsenic that exceed 10 µg/L, the limit of arsenic contaminant level in drinking water
[37], and suffer from different types of diseases from drinking arsenic-contaminated
water. The major countries that suffer from arsenic contamination are Taiwan,
Bangladesh, India, and Chile, where the arsenic concentrations in drinking water range
from 40 µg/L to 2 mg/L [38, 39], which corresponds to 532 nM and 27 µM, respectively.
In the United States, the maximum arsenic contaminant level in drinking water is 10 ppb.
However, approximately 15% of the U.S. population rely on private wells for their water
supply that were found to have arsenic levels greater than 10 ppb [40-43]. Ingesting
arsenic in naturally contaminated food and water is the most common route of arsenic
exposure. Unfortunately, it is difficult to obtain an accurate measurement of the
absorbed dose of arsenic in specific tissues, mainly due to variation among individuals
[44], including both endogenous and exogenous factors, such as gender and
occupational exposures, respectively. In 2000, Pi et al. demonstrated the average blood
arsenic level in people who were exposed to high levels of arsenic in their drinking water
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Acute Arsenic Exposure (<24 hours)
Vomiting, diarrhea, dehydration,
hypotension, abdominal pain, renal
failure

Chronic Arsenic Exposure (>3
months)
Cancer in many organs, skin pigment
changes, cardiovascular disease,
respiratory disease, diabetes,
hypertension, skin lesions, neurological
disorders

Table 1. Acute and chronic arsenic toxicological effects on human health.
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approximately for 18 years to be about 100 nM [45], which is the concentration that we
used in this thesis and from this point forward referred to as “a physiologically relevant”
level of arsenic. The lethal human adult dose for ingested arsenic is about 600 µg/kg/day
[19], which is about 60 times higher than the standard set by the EPA.
Arsenic Absorption, Distribution, Metabolism, and Excretion (ADME)
Ingestion is the main route of arsenic exposure, and arsenic is readily absorbed
from the gastrointestinal-tract (GI tract). The liver is the main site of arsenic metabolism,
and historically, methylation steps have been characterized as a critical arsenic
metabolism process. This arsenic methylation process was initially studied by Frederick
Challenger and his colleagues in the 19th century [46, 47]. In the liver, arsenic
metabolites including, monomethylarsonous acid (MMAIII), monomethylarsonic acid
(MMAV), dimethylarsinic acid (DMAIII), and dimethylarsenic acid (DMAV) are produced
(Fig. 2). When arsenate (pentavalent arsenic) enters the cells, it gets rapidly reduced to
arsenite (trivalent arsenic) [48, 49]. Arsenite, then, gets methylated by arsenic (III)
methyltransferase (AS3MT) as it attaches a methyl group. AS3MT uses Sadenosylmethione (SAM) as the methyl donor, to generate the metabolites [50]. The
average relative distribution of arsenic metabolites in the urine varies among population
groups, which suggests genetic polymorphism of human methyltransferases [51-53].
Because the methylation process is important in elimination of arsenic from the systemic
circulation, it is easy to assume that methylation is just a detoxification process of
arsenic, as it enhances excretion of arsenic from the systemic circulation. However, all
arsenic metabolites are toxic to different degrees. For example, DMAV, MMAIII and
DMAIII are observed to be more cytotoxic and genotoxic than arsenite [54-57]. Thus,
arsenical metabolites are not just the by-products of inorganic arsenic metabolism; they,
too, exert toxic effects.
Alternative schemes for arsenic metabolism were proposed. First,
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Figure 2. The metabolism pathway of inorganic arsenic. The metabolism pathway of
arsenate undergoing reduction and methylation to produce metabolites in pentavalent
and trivalent forms. The products of inorganic arsenic metabolism include MMAIII, MMAV,
DMAIII and DMAV. Unlike humans, rats can undergo another round of methylation from
DMAIII to trimethylarsine oxide (TMAO or TMAV).
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Hayakawa et al. focused on the toxicological effects of the metabolites produced by the
conventional metabolic pathway of arsenic, and the abundance of DMA from inorganic
arsenic than from MMA [58]. The group proposed the reduced form of glutathione (GSH)
is critical, and As-GSH complexes are directly involved in inorganic arsenic methylation
and important substrates for human arsenic methyltrasnferases [58]. Second, Rehman
et al. proposed a reductive methylation pathway [59]. The group proposed the
methylation reaction occurs simultaneously, instead of stepwise oxidative methylation,
by detecting trivalent form of inorganic arsenic bound to both soluble and non-soluble
proteins [59]. Nonetheless, both the conventional and the alternative pathways support
the liver serves as the major site of arsenic methylation.
Though many toxicological effects of arsenic are studied using rodent models,
the ADME of arsenic is significantly different between rodents and humans. Unlike
humans (Fig. 2), rats can metabolize further to TMAV [60]. Thus, the metabolite ratios
are different between the two species, indicating differences in metabolism. Not only
species, but also strain differences in rodents also alter sensitivity to arsenic. Thus, to
design experimental model to study human toxicological effects of arsenic using rodents
requires many considerations including, routes of exposure, dose, and strains, to make
the study applicable as possible to human exposure. Nonetheless, rodent models are
great tools to study carcinogenicity of arsenic, because the target sites of arsenic
carcinogenic effects in rodents are strongly concordant with most of the human targets
of arsenic [61].
Arsenic and Lung Cancer
i. Arsenic in Drinking Water and Lung Cancer Development
A common type of cancer in the U.S. that is induced by chronic exposure of
arsenic is lung cancer [62-64]. The two major forms of lung cancer are non-small cell
lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC). NSCLC accounts for
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more than 80% of all lung cancer. NSCLC can be divided into three major histological
subtypes: squamous-cell carcinoma, adenocarcinoma, and large-cell lung cancer.
Adenocarcinoma is the most common type of lung cancer in patients who have never
smoked. Squamous-cell carcinoma is also frequently observed in non-smokers, and is
highly associated with chronic exposure to arsenic [65, 66]. Previous studies reveal a
direct correlation between arsenic in drinking water and cancer development [39, 63, 6580]. To investigate a direct environmental factor that is associated with lung cancer
development in individuals who have never smoked, Putila and Guo identified a positive
correlation between arsenic levels and lung cancer incidence [63]. This study
underscored the association between arsenic and lung cancer, independent of smoking
and socioeconomic status in the United States [63]. Particularly, people who reside in
the Appalachian portion of Kentucky have a higher incidence of lung cancer due to coal
mining in Appalachia [81], as arsenic is naturally found in rocks and coal. This direct
relationship between arsenic and lung cancer was also observed in countries that have
high levels of arsenic in drinking water that can range up to 300 µg/L, which
approximately corresponds to 4 µM, and these countries had some of the highest
incidences of lung cancer in the world [74, 79, 82-84]. In Bangladesh, 1 in 16 cancer
deaths are attributable to arsenic exposure in drinking water [85].
ii. Early Life Exposure to Arsenic and Lung Cancer
Not only post-natal arsenic exposure, but also pre-natal arsenic exposure can
lead to lung cancer as well. As pre-natal stage is a critical period of development, young
individuals in Chile, who had in utero-only and/or early-life arsenic exposure
concentrations nearly up to 1,000 µg/L, developed lung cancer [86]. Consistently, when
pregnant mice received 85 ppm arsenic-contaminated water only during pregnancy
(gestation days 8 to 18), the offspring had lung tumor formation in adulthood [87]. These
studies highlight the lethality of pre-natal exposure to arsenic, as the placenta cannot
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serve as a barrier to arsenic. A study compared the cancer progression in mice with
whole-life 24 ppm arsenic exposure (exposure after birth and termination months before
a full life span [88]) and in utero-only 85 ppm arsenic exposure (gestation days 8 to 18),
and observed development of lung adenocarcinoma and hepatocellular carcinoma in
both groups of mice with whole-life and in utero-only exposure [89]. However, there were
higher incidences of cancer development in offspring that had whole-life arsenic
exposure. This result suggests whole-life arsenic exposure, or post-natal arsenic
exposure, can aggravate the tumor progression [90-92].
iii. In vitro and In vivo Studies of Arsenic and the Effects on Lung
Both in vitro and in vivo models are used to measure toxicological effects on lung
and to understand arsenic-induced lung cancer development. The majority of in vitro
studies use non-malignant cell lines with chronic arsenic exposure, and the reported
toxicological effects include increased cell proliferation, colony formation, cell
transformation, and ROS induction [93-96]. Furthermore, lung adenocarcinoma
development is predominantly observed in in vivo model in response to chronic arsenic
exposure [87, 89, 91, 97]. The in vitro and in vivo studies of arsenic and the effects on
lung are summarized in Table 2.
iv. Proposed Mechanisms of Arsenic-induced Carcinogenesis
Proposed mechanisms of arsenic-induced carcinogenesis include oxidative
stress [98-104], epigenetic changes including histone modification, miRNA expression,
and DNA methylation [105-116], aneuploidy [117], and activation of oncogenic pathways
[118-136], such as the epidermal growth factor receptor (EGFR). The EGFR is a wellestablished biomarker of cancer [137-140], and studies have found the EGFR is
overexpressed in a variety of tumors and cancer cells, which correlates with poor patient
prognosis [141-156], including NSCLC [157-159]. Both previous studies and our
preliminary data have shown acute arsenic exposure induces overexpression of EGFR
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Type of
Study

Target
Organ

In vitro

Lung

Cell type
or Animal
Strain
Beas-2B
Beas-2B

Beas-2B

Beas-2B

In vivo

Arsenic
Exposure

Pathological
Phenotype

10 µM for 24
hours
0.25, 1, and 5
µM for 26
weeks

Overexpression of
EGFR
Increased cell
proliferation, anchorageindependent growth,
ROS levels, and colony
formation
Increased ROS levels,
cell transformation

[160]§*

Increased cell
transformation, ROS
levels, activation of
STAT3,
Increased cell
transformation,
percentage of cells in
G2/M and S phases,
colony formation,
chromosome aberration
Activation of Erk, NF-κB,
increased cell
transformation
Activation of STAT3

[95]

Lung adenoma,
carcinoma incidence

[89, 91]

Lung adenocarcinoma,
bronchiolo-alveolar
tumors formation

[87, 91, 97]

5 µM for 6
hours, 0.25
µM for 24
weeks
0.125, 0.25,
and 0.5 µM
for 6 months

16-HBE

2.5 µM for 13
weeks

HELF

1 µM for 15
weeks

HBE

1 µM for 3
hours
Gestation day
8 to 18 (42.5,
85 ppm),
Gestation day
8 to 18 (85
ppm).
Whole-life
exposure

C3H, CD1

CD1

Table 2. In vitro and In vivo studies of arsenic and the effects on lung
*= acute arsenic exposure; §= Effect on EGFR expression
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in human bronchial epithelial cells [160] (Fig. 3). Despite a direct association between
supraphysiological levels of arsenic and lung cancer, how chronic exposure to “a
physiologically relevant” level of arsenic affect EGFR expression and signaling are not
known.
EGFR Biology
i. Structure and Activation of EGFR
EGFR is a receptor tyrosine kinase (RTK) localized on the cell surface (Fig. 4).
As one of the ErbB family receptors (EGFR, ErbB2, ErbB3, and ErbB4), EGFR is
activated by specific ligands, and there are 7 endogenous EGFR ligands (epidermal
growth factor (EGF), transforming growth factor-α (TGFα), HB-EGF, amphiregulin
(AREG), betacellulin (BTC), epigen (EPGN), epiregulin (EREG)). Of these ligands, HBEGF and BTC are known to have high affinity for the receptor and have relatively high
downstream effects [163-165]. The EGFR and the other ErbB family members can be
divided into three main domains: extracellular domain, transmembrane domain, and
intracellular domain, which consists of kinase domain and tyrosine residues on the C
terminus that serve as docking sites for many downstream proteins. Ligand binding to
the extracellular domain of the EGFR leads to a conformational change that allows
receptor dimerization and activation of the intrinsic kinase activity. Once activated, the
kinase from one receptor trans-phosphorylates tyrosine residues on the intracellular
carboxy-terminus of its receptor pair (Fig. 4). These newly formed phosphotyrosines
then serve as docking sites for downstream signaling proteins (effectors) that mediate
cell proliferation, survival, tumorigenesis, and differentiation.
ii. EGFR Function in Epithelial Development
The EGFR is a critical component in development. The EGFR expression was
observed in embryogenesis, and its ligands, specifically EGF and TGFα, were also
expressed from 4- to 8-cell stage of embryogenesis [166-171]. The co-localization of the
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Figure 3. Acute arsenite induces overexpression of EGFR. Immunblot of EGFR and
phosphotyrosine 1068 (pY1068) in Beas-2B cells treated with arsenite at the indicated
concentrations for 24 hours. 10 ng/mL of EGF treatment in Beas-2B cells was used as a
positive control. EGF was stimulated after 2 hours of serum-starvation, and it was
stimulated for 7 minutes. The samples were resolved on 7.5% SDS-PAGE.
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Figure 4. EGFR structure. When the receptor is not occupied by a ligand, the cysteinerich regions of the extracellular domain of the receptor interact with each other and
maintain a “closed” conformation. When a ligand binds to the ligand binding domains of
the extracellular domain, the EGFR undergoes a conformational change, exposing
cysteine-rich regions. These regions, then, interact with other exposed cysteine-rich
regions of another ErbB family receptor. This allows receptor dimerization and activation
of the intrinsic kinase activity. Once activated, the intracellular kinase from one receptor
trans-phosphorylates tyrosine residues on its receptor pair. These newly formed
phosphotyrosines then serve as docking sites for downstream signaling proteins that
mediate cell proliferation, survival, tumorigenesis, and differentiation. Red=ligand;
green=cysteine-rich regions; blue=ligand-binding domains; purple=inactive kinase
domains; yellow=active kinase domains.
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ligands with the EGFR throughout the critical stages of embryogenesis underscores the
requirement of full activation of EGFR for proper development. Therefore, EGFR null
and/or EGFR mutations are deleterious. Earlier studies have found EGFR null mice were
either embryonically lethal or died shortly after birth [172]. The mice that had EGFR
mutation manifested changes in hair and skin, which support the roles of EGFR in
epithelial development [173, 174].
iii. The Endocytic Trafficking Pathway of EGFR
When a ligand binds to the EGFR, the activated EGFR gets internalized via
clathrin-coated pits into the cell. Once the clathrin is shed, the vesicle then fuses with the
early endosomes [175]. From the early endosomes, the receptors can have two different
fates; the receptors can move back to the plasma membrane from the early endosomes
(recycling), or the receptors can be degraded via lysosomes. For receptors to degrade,
the receptors-containing early endosomes increase acidity to “mature” into the late
endosomes [176]. The late endosomes then fuse with lysosomes to degrade the
receptors (Fig. 5). The degradation of EGFR is tightly regulated to control the
downstream signaling events, such as proliferation. Thus, improper regulation of
degradation of EGFR can lead to overstimulation of proliferative signaling and contribute
to cancer development. When the receptors are activated, the tyrosine residues of the
kinase domain of the receptors get phosphorylated and get internalized into the cell. This
receptor activation triggers c-Cbl, which is an E3 ubiquitin ligase, to be recruited and
binds to a specific phosphorylated tyrosine residue (pY1045) of the kinase domain of the
receptor [177]. This binding causes ubiquitination of the receptors and the receptors get
marked for degradation via lysosomes [178, 179]. As mentioned earlier, the other fate of
the internalized receptors is to recycle back to the plasma membrane. Previous studies
have found even without any ligand stimulation, about 10% of the EGFR constitutively
internalize and recycle back to the plasma membrane [180], predominantly by the basal
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Figure 5. The endocytic trafficking pathway of EGFR. When a ligand binds to the
receptor, the receptors become activated. The activated tyrosine kinase domains then
induce trans-phosphorylation of the tyrosine residues on the carboxy-terminus of its
receptor pair. This phosphorylation triggers c-Cbl to be recruited to the activated
receptors and ubiquitinates the receptors. The activated receptors get internalized via
clathrin-coated pits into the cell. Once the clathrin is shed, the vesicle then fuses with the
early endosomes. From the early endosomes, the receptors can have two different fates;
the receptors can move back to the plasma membrane from the early endosomes
(recycling), or the receptors can be degraded via lysosome.

17

expression of TGFα, an EGFR ligand that is involved in the recycling of the receptors
[181]. EGF, on the other hand, is a well-known EGFR ligand, and EGF-stimulated EGFR
undergo degradation. The different effects between TGFα and EGF ligands are mainly
due to their sensitivity to the acidic environment [182]. TGFα is pH sensitive, and it is
known to dissociate from the receptors at pH of about 6.8, whereas EGF get dissociated
from the receptors at pH of about 5.8 [183-185]. Thus, TGFα gets dissociated from the
early endosome compartment (pH of about 6.8), which allows the EGFR to recycle back
to the plasma membrane, whereas EGF:EGFR complex endure the acidic environment
until they get degraded [185]. The ErbB2 expression levels also affect the recycling
pathway of the receptors. Previous studies have observed decrease in EGF-stimulated
EGFR degradation in cells that overexpress ErbB2 [186, 187]. Further studies supported
these observations by demonstrating ErbB2 overexpression preventing clathrinmediated endocytosis of EGFR [186, 188]. However, a clear mechanism for ErbB2induced impairment of EGFR endocytosis remains elusive.
EGFR and Cancer
There are four main events that can perturb the EGFR regulatory mechanisms,
which all contribute to cancer development: 1) overexpression of EGFR,
2) overproduction of its ligands, 3) improper receptor trafficking, and 4) the EGFR kinase
domain mutations.
i. Overexpression of EGFR
The overexpression of EGFR (as compared to adjacent non-cancerous tissue) is
seen in many cancers, including colorectal cancer, pancreatic cancer, NSCLC [159, 189195], and gliomas [196-201], and is associated with a poor prognosis. Under
pathological conditions, such as cancer, the normal regulatory mechanisms of the
signaling pathways are perturbed, resulting in hyperactivation of the signaling pathways.
The overexpression of EGFR and its association with a poor prognosis can be explained
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by increased sites for the ligands to bind to the receptors, leading to enhanced
downstream signaling events, such as proliferation.
ii. Overproduction of the EGFR Ligands
An increase in synthesis of ligands above the basal levels also triggers
enhancement of the EGFR-induced activation of proliferative pathways. High levels of
EGFR ligands, including EGF, TGFα, AREG, and BTC, were observed in cancers [202,
203]. The frequency of overexpression in protein levels of the EGFR and TGFα, has
been observed in NSCLC patients, and predicts a poor outcome [190]. All ligands
function similarly to EGF; they bind to the ligand binding domain of the receptors, and
induce a conformational change in the receptors that leads to dimerization of the
receptors and increased tyrosine kinase activity. However, their tissue distribution,
expression regulation, and binding affinity and preferences on the receptors differ from
one another, which all can alter the EGFR signaling by changing the endocytic trafficking
itinerary [204-208].
iii. Improper Receptor Trafficking
Disruption of proper EGFR trafficking is known to contribute to cancer
development [209-216] mainly due to poor downregulation of the receptors and
sustained downstream proliferative signaling. Without any ligand stimulation, the
unstimulated receptors predominantly localize on the surface of the cells. However,
when the cells are stimulated with ligand, such as EGF, the internalized receptor colocalizes with the early endosomes within 10 minutes post-stimulation [217]. Over time,
the EGF-stimulated cells will have reduced staining of the EGFR in the early endosome
compartment, due to its lysosomal degradation. However, when the EGFR endocytic
trafficking pathway is perturbed, specifically between the early and the late endosomes,
the EGFR will remain in the early endosome compartment and still active, prolonging the
signaling as the EGFR accumulate in the early endosome compartment [218].
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Consistently, a previous study observed an increase in the EGFR protein expression
level in response to prevention of the EGFR degradation [213], which suggests improper
EGFR endocytic trafficking can contribute to both overexpression and hyperactivation of
EGFR, leading to carcinogenesis. Thus, abnormalities in the endocytic trafficking of
signaling receptors are now well-established hallmarks of malignant cells [219, 220].
iv. Kinase Domain Mutations.
Not only overexpression of the wild type EGFR, but also expression of the
mutant EGFR kinase domain can contribute to cancer development. The most common
EGFR kinase domain mutation is EGFRvIII, which is a deletion of residues from 6 to
273. Despite the inability to bind to the ligands, EGFRvIII is known to induce constitutive
activation and trigger downstream signaling [221]. This form of receptor is known to
enhance tumorigenesis, proliferation, and metastasis of tumors [222-225]. Such
mutation is commonly observed in about 40% of glioblastoma cases [226-228]. Even
though the overexpression of EGFR is commonly observed in NSCLC cases, there are
only about 10 to 30% of NSCLC patients who are EGFR mutant positive [229]. The most
common EGFR kinase domain mutations in NSCLC patients are exon 19 deletion, which
is near the ATP-binding pocket that tyrosine kinase inhibitor (TKI) targets, and a
mutation in exon 21 by substituting leucine 858 with arginine, or L858R [221, 230].
These kinase mutations cause constitutive activation of the EGFR by destabilizing the
inactive conformation of EGFR [231, 232]. Therefore, NSCLC patients with the EGFR
kinase domain mutations have better clinical response to TKI, as the mutants are more
sensitive to TKI than the wild type EGFR [233, 234]. Unfortunately, patients with mutant
EGFR kinase domain acquire resistance to the TKI therapy. A common EGFR kinase
domain mutation that leads to resistance is T790M (substitution of threonine 790 with
methionine). The location of T790 is significant, as it is located in the ATP binding pocket
[235]. This substitution allows structural conformation of the receptors to gain near wild
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type levels of ATP affinity and allow ATP to bind to the kinase domain with higher affinity
than the drug [235, 236], which supports T790M-induced resistance to TKI. Additionally,
Shtiegman et al. observed decrease in endocytosis and downregulation of L858R- and
T790M-containing EGFR, and continuous phosphorylation status of the receptors
several hours following EGF stimulation, unlike the wild type receptors [211], which
suggests prolonged downstream signaling and predisposition to lung cancer.
Particularly, L858R-containing EGFR mutant had impaired recruitment and
phosphorylation of c-Cbl with EGF stimulation [211].
v. EGFR-targeted Chemotherapy
Because of the importance of EGFR in cancer development, there have been
several chemotherapeutic agents that target EGFR. The EGFR-targeting
chemotherapeutic agents can be divided into two main classes: monoclonal antibodies
and small molecule kinase inhibitor. An example of the monoclonal antibody is
Cetuximab, which targets the extracellular domain of the receptor to prevent
ligand:receptor interactions. This drug is approved for treatment of cancers, such as
colorectal cancer and squamous cell carcinoma of the head and neck (NCI, 2018).
Erlotinib and getfitnib are examples of TKI, which bind to the kinase domain of the
receptor to prevent activation of the downstream proteins and their signaling. Erlotinib is
widely used as first-line therapy to treat particularly NSCLC patients [237]. As mentioned
earlier, patients with mutant EGFR, such as L858R, have good responses to TKI, as
they induce constitutive activation of the kinase, and such activity is found to increase
sensitivity to the drug [233, 234, 238]. These specific mutations have higher affinity for
TKI than does the wild type EGFR, and they have lower affinity for ATP, as compared to
the TKI [231, 239]. Consistently, NSCLC cells with the mutant EGFR kinase domain
have lower IC50 value of TKI, as compared to the wild type EGFR [240]. Furthermore,
TKI inhibited both EGFR activation and proliferation, and induced apoptosis in NSCLC
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cells with the mutant EGFR kinase domain, but it did not induce apoptosis in NSCLC
cells with the wild type EGFR [233, 241, 242]. Interestingly, when the ErbB2 expression
was blocked by monoclonal antibodies, enhancement of the mutant receptors’
downregulation was observed [211], which highlights the importance of ErbB2
regulation. Thus, these studies suggest the complexity of the mutant receptors, and
more specific targets-driven chemotherapeutic agents are needed. There are several
irreversible inhibitors that target these mutations, and they act through covalent binding,
but they are yet to be approved [235].
EGFR and Arsenic-induced Carcinogenesis
As mentioned above, both previous studies and our preliminary data have shown
acute high levels of arsenite exposure induces the overexpression of EGFR in human
bronchial epithelial cells [160] (Fig. 3). Understanding the molecular mechanism of such
phenomena will contribute to developing new drug target. This thesis examines the
effect of “a physiologically relevant” level of arsenite on the EGFR signaling.
Arsenic readily accumulates in epithelial cells as they have high content of thiol
groups, and EGFR plays a critical role in epithelial development. The interaction
between arsenic and thiol groups supports arsenic role in lung cancer development
through EGFR signaling axis in epithelial cells. In this thesis, we suggest a potential role
of chronic arsenite exposure in the regulation of components of the EGFR signaling axis.
A previous study used micromolar range of arsenite, and observed increased level of
EGFR ligand mRNAs, specifically HB-EGF [119]. HB-EGF is seen in a variety of
cancers, such as colorectal, cervical, breast and gastric cancers [243-247]. Consistently,
an earlier study demonstrated increase in TGFα mRNA expression levels in mice
chronically exposed to arsenic-contaminated drinking water [248]. Also, overexpression
of TGFα was observed in the tumor from nearly 50% of primary NSCLC patients [190].
As mentioned earlier, TGFα is an EGFR ligand that is involved in the constitutive
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recycling of EGFR, which can delay the EGFR lysosomal degradation [181], resulting
overexpression of the receptors. Thus, these studies support the hypothesis that arsenic
has an impact on regulation of the ligands, resulting in overexpression of the EGFR.
There is a scant amount of studies that observed the effect on the receptor
trafficking upon chronic toxicant exposure. A study has shown arsenic increases protein
levels of Rab4, a protein involved in the recycling of EGFR [249]. This study suggests a
potential role of arsenic in altering the endocytic trafficking of EGFR. Under normal
conditions, EGFR internalizes via clathrin-mediated endocytosis, but at high doses of
EGF, the EGFR undergoes clathrin-independent endocytosis, including caveolinmediated endocytosis [250]. This interplay between clathrin-mediated endocytosis and
caveolin-mediated endocytosis controls the expression of EGFR in the cells to prevent
overstimulation, as caveolin-mediated endocytosis preferentially couples to the EGFR
degradation [251]. In our preliminary study, we observed overexpression of EGFR in
response to chronic arsenic exposure (Fig. 7), suggesting a possible role of arsenic in
dysregulating the interplay between the two distinct endocytic trafficking pathways,
which contributes to arsenic-induced carcinogenesis by allowing overstimulation of
EGFR signaling. Additionally, acute high levels of arsenic exposure is known to prevent
microtubule disassembly by losing the integrity of the tubulins and mircotubules [252],
and microtubules are critical component in movement of proteins between the organelles
[253]. Thus, the EGFR endocytic trafficking pathway is a potential target site of chronic
arsenic to induce overexpression of EGFR in the cells. Disruption of proper EGFR
trafficking is known to contribute to cancer development, such as lung, pancreatic, and
breast cancers [211, 213, 254]. Despite of the importance of proper EGFR trafficking in
cancer development, there has been no study that tested alterations in the route of
EGFR trafficking from chronic arsenic exposure.
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Importance of the study
There are several chemotherapies for lung cancer; however, cancer cells acquire
resistance to therapy, as they find alterative routes to survive. More specific cellular
targets are needed to be found, and an understanding of the underlying mechanisms to
cancer development is critical. The present study was achieved by using Beas-2B cells,
which are non-malignant human lung bronchus epithelial cells generated by SV40
transfection [255]. They have been widely used to study heavy metal-induced
carcinogenesis [256-260], and they are commonly used in arsenic studies because the
lungs are known to be the major target of inorganic arsenic carcinogenesis [62, 261].
The long-term goals are to understand the molecular mechanisms of arsenite-induced
overexpression of EGFR and to identify novel roles of chronic arsenite exposure in the
EGFR endocytic trafficking.
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CHAPTER 2
MATERIALS AND METHODS

Cell culture
Human bronchial epithelial cells, Beas-2B cells obtained from ATCC were grown in LHC9 media (Gibco) supplemented with or without 100 nM of sodium arsenite (Fisher
Scientific) on a matrix of 10 µg/mL of fibronectin and 35 µg/mL of collagen (FNC Coating
Mix, AthenaES). This concentration of sodium arsenite (arsenite) was selected based on
the average blood arsenic level in people who were exposed to high levels of arsenite in
drinking water [45]. Cultures were grown in 5% CO2 at 37°C atmosphere. Multiple
cultures of cells (4 with and 4 without 100 nM sodium arsenite) were maintained
separately for 24 weeks. Cells were propagated by splitting at 1 x 106 cells/ 10 cm dish
every 3-4 days. Once a week, the arsenite treated cells were frozen down at 1 x 106
cells/vial and stored in liquid nitrogen.
Immunoblotting
Cells were washed with phosphate-buffered saline (PBS), and kept in EDTA/PBS
solution for 15 minutes at 37°C to allow non-enzymatic dissociation of cells. Then the
cells were harvested in RIPA buffer [150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, 50
mM Tris (pH 8.0)] containing protease inhibitor, PMSF (EMD Millipore)]. The samples
were diluted in the 6X SDS buffer containing 10% βME, then the samples were boiled at
95°C for 3 minutes prior to gel loading. The lysates were separated by 7.5% SDS-PAGE
gel and transferred onto a nitrocellulose membrane. The membrane was blocked with
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5% milk/TBST before probing with primary antibody overnight at 4°C. The following
antibodies were used for protein detection: EGFR (Santa Cruz, sc-03) (1:1000 dilution in
5%milk/TBST), pY1068 (Cell Signaling, 2234L) (1:500 dilution in 5%milk/TBST), and αtubulin (Sigma-Aldrich, T6199-200UL) (1:4000 dilution in 5%milk/TBST). After incubation
with the horseradish peroxidase-conjugated secondary antibody (anti-mouse or antirabbit, Thermo Fisher), we used enhanced chemiluminescence (ECL) to visualize the
proteins using a Fotodyne imaging system. The immunoblot was analyzed and
quantified using ImageJ software.
Indirect Immunofluorescence
Beas-2B cells were cultured on sterile 12mm round #1 glass cover slips for 2 days. The
cells were serum-starved for 2 hours prior to EGF stimulation. After 15 minutes of EGF
stimulation, cells were washed with PBS++ (PBS with 0.5 mM Ca2+, 0.5 mM Mg2+). The
cells were fixed in 4% paraformaldehyde/PBS++ for 5 minutes at room temperature
followed by 15 minutes incubation on ice. After PBS++ washes, the cells were
permeabilized in blocking buffer (0.1% saponin, 5% FBS in PBS++) for 15 minutes at
room temperature. After washes with PBS++, the cells were incubated with the indicated
primary antibody [EGFR (Ab-1, EMD Millipore, GR01)] in the blocking buffer (1:1000
dilution) for 60 minutes at room temperature. After 3 washes with PBS++, the cells were
then incubated with fluorophore-conjugated secondary antibody (Alexafluor-488, Lifetechnologies) in the blocking buffer (1:250 dilution) for 60 minutes at room temperature
in the dark. After 6 washes with PBS++, the glass cover slips were dipped into beaker
with ddH2O to remove associated salts. Kimwipes were used to carefully remove excess
liquid on the cover slips. The coverslips were mounted onto slides using Prolong Gold
Antifade Mountant with DAPI (Thermo-Fisher Scientific). The slides were cured in the
dark overnight and examined the next day using a Nikon Eclipse Ti-E Inverted
fluorescence microscope, using Nikon NIS Elements software. The images were taken
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with a 60X oil immersion objective lens. Multiple images were acquired and
representative images are presented. A total of 100 cells from randomly selected fields
were imaged.
Alamar Blue assay
Beas-2B cells were plated onto 96-well microplates (10,000 cells/well) for 24 hours.
Cells were treated with different concentrations of AG1478 (Cayman Chemical), and
0.1% of DMSO was used as a control. Cells were incubated with AG1478 for 24 hours.
Then, 10 µL (10% of total volume) of Alamar Blue Reagent (Bio-Rad) was added to each
well of the 96-well microplate. After cell incubation for 2 hours at 37°C, the fluorescence
of each well was measured in plate reader with Gen5 BioTek software at 530nm of
excitation wavelength and 590nm emission wavelength. The data were plotted as the
percentages of the cell viability vs. the increasing concentrations of AG1478.
RT-qPCR
RNA was isolated from Beas-2B cells by using RNAqueous-Micro Total RNA Isolation
Kit (Thermo Fisher, AM1931). cDNA was synthesized using High-Capacity cDNA
Reverse Transcription Kits (Thermo Fisher, 4368814). qPCR was performed using
TaqMan Gene Expression Master Mix (Thermo Fisher, 4369016), and the primers were
commercially designed by Thermo Fisher. The following primers were used for qPCR
analysis: EGFR (Catalog# 4331182, Assay ID Hs01076089), ErbB2 (Catalog# 4331182,
Assay ID Hs01001580_m1), AREG (Catalog# 4331182, Assay ID Hs00950669_m1),
BTC (Catalog# 4331182, Assay ID Hs00156140_m1), and TGFα (Catalog#4331182,
Assay ID Hs00608187_m1). All primers have been validated either by the company itself
or in the literature. The 96-well plate (Thermo Fisher, 4346906) was read in
StepOnePlus System (Thermo Fisher, 4376600). GAPDH was used as a housekeeping
gene. For each experiment, gene expressions (average of the technical replicates) were
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normalized to the average GAPDH levels. Data were plotted as the fold difference
compared to the untreated Beas-2B cells at week 0.
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CHAPTER 3
RESULTS
The overarching goal of these experiments was to understand the molecular
mechanisms of arsenite-induced overexpression of EGFR and to identify novel roles of
chronic arsenite exposure in the EGFR endocytic trafficking. We hypothesized
carcinogenicity of chronic arsenite exposure induces improper endocytic trafficking of
EGFR, resulting EGFR overexpression.
Chronic arsenite exposure does not alter the morphology of Beas-2B cells.
As a typical epithelial morphology, Beas-2B cells maintain cell-to-cell adhesion,
cell polarity, and have projectile morphology (Fig. 6). The cell morphology can change in
response to heavy metals, such as chromium, by altering cell-cell contact, and losing the
formal shapes [262]. To test whether low levels of arsenite alter the morphology of the
cells, Beas-2B cells were grown in the presence of 100 nM arsenite for 24 weeks.
Interestingly, we did not observe any morphological changes, as compared to the
passage-matched untreated cells and 0 week Beas-2B cells (Fig. 6).
Chronic arsenite exposure induces overexpression of EGFR.
Overexpression of EGFR in response to acute micromolar range of arsenite
exposure is now well-established [120, 160] (Fig. 3). To determine whether chronic
exposure to “a physiologically relevant” level of arsenite (100 nM) stimulate the EGFR
levels in a similar way, the EGFR and phosphotyrosine (pY1068) levels were measured
in cells that were grown in arsenite for 24 weeks. As a measure of EGFR
phosphorylation (activity), pY1068 levels were monitored. The passage-matched
untreated Beas-2B cells were used as a negative control to make sure the cells’
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Figure 6. Chronic arsenic treatment does not alter the morphology of Beas-2B
cells. The Beas-2B cells were grown in the presence of 100nM arsenic for 24 weeks,
and the morphology was compared to the passage-matched untreated Beas-2B cells
and 0 week Beas-2B cells.
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characteristics did not change over time. We did not observe any differences in the
expression levels of both EGFR and pY1068 among the passage-matched untreated
cells (Fig. 7). Similarly to acute exposure of arsenite, chronic low levels of arsenite, too,
induced the overexpression of EGFR (Fig. 7). When 24-weeks arsenite treated cells
were co-treated with AG1478, a small molecule inhibitor of the kinase domain, the
expression level of pY1068 significantly decreased, which suggests arsenite acts directly
on the tyrosine kinase domain, rather than via another protein (i.e. a non-receptor
tyrosine kinase) to induce autophosphorylation of the EGFR (Fig. 8). The expression
level of pY1068 of the untreated cells establishes the basal level of EGFR
phosphorylation (Fig. 8, lane 1).
Chronic arsenite exposure increases the mRNA levels of EGFR ligand, TGFα.
To understand the underlying mechanism of arsenite-induced overexpression of
EGFR, we investigated mRNA levels of the ErbB family receptors, as well as their
ligands. RT-qPCR data showed chronic exposure of “a physiologically relevant” level of
arsenite increases TGFα mRNA levels in an exposure time-dependent manner (Fig. 9).
Chronic arsenite exposure alters the route of the EGFR endocytic trafficking
pathway.
Previous studies have observed increase in protein and mRNA levels of proteins
that are highly involved in the recycling of EGFR in response to acute arsenite exposure
[248, 249, 252]. However, whether arsenite alters the EGFR endocytic trafficking
pathway still remains elusive, thus we wanted to determine any alterations in the route of
the EGFR endocytic trafficking pathway when the cells are chronically exposed to “a
physiologically relevant” level of arsenite. The EGFR in the untreated Beas-2B cells
were punctate and randomly scattered, but when the cells were exposed to 100 nM of
arsenite for 24 weeks, the route of EGFR trafficking was altered; the EGFRs were
aggregated (Fig. 10). However, due to obscurity in the EGFR localization, further studies
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Figure 7. Chronic exposure to low levels of arsenite induces EGFR
overexpression and activity. 10 ng/mL of EGF was stimulated after 2 hours of serumstarvation, and it was stimulated for 7 minutes. The samples were resolved on 7.5%
SDS-PAGE. The EGFR and pY1068 expression levels of Beas-2B cells that were
treated with arsenite were compared with the passage-matched untreated cells.
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Figure 8. AG1478 prevents chronic-arsenite induced EGFR activity. The EGFR and
pY1068 expression levels were measured in the cells that were grown in arsenite, EGF,
or AG1478. 10 ng/mL of EGF was stimulated after 2 hours of serum-starvation, and it
was stimulated for 7 minutes. The cells were exposed to 30 nM of AG1478 for 24 hours.
The samples were resolved on 7.5% SDS-PAGE.
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Figure 9. Chronic arsenite increases mRNA levels of EGFR ligand, TGFα. RNA was
isolated from Beas-2B cells (untreated, 6 weeks, 12 weeks, 18 weeks, and 24 weeks)
and cDNA was synthesized. qPCR was performed using the primers that were
commercially designed. For each experiment, gene expressions (average of the
technical replicates) were normalized to the average GAPDH levels. Data were plotted
as the fold difference compared to the untreated Beas-2B cells at week 0. (N=2)
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Figure 10. Chronic arsenite exposure alters the route of the EGFR endocytic
trafficking pathway. Immunofluorescence was performed to analyze the EGFR
trafficking in response to chronic arsenic exposure. Cells were fixed with 4%
paraformaldehyde and stained for EGFR (Alexafluor-488 (Green)). Scale bar=10 µm
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are needed to draw conclusions.
Chronic arsenite does not sensitize Beas-2B cells to tyrosine kinase inhibitor.
Because we observed chronic arsenite-induced EGFR overexpression, we next
wanted to determine how chronic exposure to “a physiologically relevant” level of
arsenite treatment affects cell sensitivity to tyrosine kinase inhibitor. Tyrosine kinase
inhibitor is a well-established EGFR-targeted chemotherapy. A previous study has
shown overexpression of EGFR in thyroid cancer cells increases its sensitivity to a wellknown tyrosine kinase inhibitor, getfitnib [149]. Because arsenite stimulates
overexpression of EGFR, we performed Alamar Blue assay to determine whether
chronic arsenite alters the sensitivity of Beas-2B cells to AG1478. AG1478 is known to
share the same structural backbone with getfitnib [263], and it is known to have the
same biological function as getfitnib [264]. We performed the assay by using different
concentrations of AG1478 (10 nM, 30 nM, 100 nM, 300 nM, 1 µM, 3 µM, 10 µM, 30 µM,
100 µM) and measured cell viability. The overall trend of dose-response between the
untreated and the 24-weeks arsenite treated cells was comparable (Fig. 11). Thus, there
were no changes in sensitivity to AG1478 in the chronic arsenic-treated Beas-2B cells.
Chronic arsenite may prevent EGFR lysosomal degradation.
A previous study observed prevention of the EGFR degradation in response to
acute arsenite exposure, and this phenomenon persisted with cyclohexamide treatment
[265]. To determine whether the overexpression of EGFR is mediated by arseniteinduced prevention of the EGFR lysosomal degradation, we performed immunoblot on
EGF-treated cells to measure the EGFR and pY1068 expression levels in the absence
and presence of 24-weeks of arsenite exposure, and stimulated with 50 ng/mL of EGF
with selected time points (0, 5, 10, 20, 40, 60 minutes) to analyze the EGFR protein
degradation efficiency. We predicted, with time, we would observe prevention of EGFR
degradation in arsenite-treated cells, as compared to the untreated cells. Although the
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Figure 11. Chronic arsenite does not sensitize Beas-2B cells to tyrosine kinase
inhibitor. Alamar Blue assay was performed to measure and compare the cell viability
of 24 weeks arsenite-treated cells and the passage-matched untreated cells in response
to different concentrations of AG1478 for 24 hours. (N=2)
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kinetics of EGFR degradation were not altered with arsenite treatment, the overall
protein expression levels of the EGFR and its activity were stronger in the arsenitetreated cells than in the untreated cells (Fig. 12).
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Figure 12. Chronic arsenite may prevent degradation of EGFR. Immunoblot was
performed to measure any prevention in the EGFR degradation in response to 24-weeks
of arsenic treatment. The EGFR and pY1068 expression levels were measured in cells
that were grown with or without 100 nM of arsenite. Beas-2B cells were treated with 50
ng/mL of EGF for selected time points, after 2 hours of serum-starvation. The samples
were resolved on 7.5% SDS-PAGE.
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CHAPTER 4
DISCUSSION
The overall purpose of this work was to identify novel roles of chronic arsenite
exposure in cancer development to mitigate arsenite toxicity. Acute high levels of
arsenite-induced EGFR overexpression have been well-established based on previous
studies and our own preliminary data [120, 160] (Fig. 3). In this thesis, we examined the
effect of “a physiologically relevant” level of arsenite on the EGFR signaling. This study
was achieved by first, performing immunoblot to support chronic arsenite exposure does
increase EGFR expression levels and activity (Fig. 7A, B). Our results were consistent
with previous studies that observed the activation of EGFR in response to chronic
arsenite exposure [93, 119]. We also measured the expression levels and the activity of
EGFR in response to AG1478 exposure to determine whether arsenite acts directly on
the kinase domain to induce autophosphorylation of the EGFR. We observed decrease
in EGFR expression and activity in both of the untreated and the arsenite-treated cells
when the cells were exposed to AG1478 (Fig. 8). With 30 nM AG1478 treatment, a
nearly complete inhibition of the EGFR activity (pY1068) was observed (Fig. 8),
however, there is no clear explanation to decreased protein expression level of the
EGFR in both untreated and arsenic-treated cells. One possible explanation is that
AG1478 prevents activation of EGFR downstream signaling, resulting prevention of
further EGFR synthesis.
Previous studies support a role of arsenite in inducing expression levels of
protein and mRNA that are highly involved in the trafficking, such as TGFα [248] and
Rab4 [249], respectively. As mentioned earlier, TGFα is an EGFR ligand that is involved

40

in the constitutive recycling of EGFR, which can delay the EGFR lysosomal degradation
[181], resulting the overexpression of the receptors. Rab4, too, is a protein that is
involved in the recycling of EGFR [249]. Additionally, acute high levels of arsenite
exposure is known to prevent microtubule disassembly by losing the integrity of the
tubulins and mircotubules [252], and microtubules are critical component in movement of
proteins between the organelles [253]. As a result, the EGFR endocytic trafficking
pathway could be a potential target site of chronic arsenite exposure to induce the
overexpression of EGFR in the cells. We performed immunofluorescence to analyze any
changes in the trafficking of EGFR in response to chronic arsenite exposure. Based on
our immunofluorescence results, we observed alterations in the trafficking of EGFR, but
it is unclear whether the receptors are localized on the cell surface or inside the cell.
Further studies, such as confocal analysis and co-localization immunofluorescence, are
needed to draw conclusions on their altered trafficking phenotype in response to chronic
arsenic exposure. There are several possibilities; 1) chronic arsenite exposure may
prevent the EGFR to transport from the ER-Golgi intermediate compartment (ERGIC) to
the plasma membrane, 2) chronic arsenite exposure may prevent lysosomal degradation
of EGFR by inducing accumulation of the EGFR in the early endosomes and allow
constitutive downstream signaling, or 3) chronic arsenite may allow continuous recycling
of the EGFR from the early endosomes to the plasma membrane by overexpressing the
proteins that are involved in the recycling, such as Rab4. The possibility of EGFR
accumulation in the ERGIC is likely, because chronic arsenic exposure may prevent
EGFR endocytic transport by hindering microtubule disassembly, as a previous study
has shown acute high levels of arsenic exposure prevent microtubule disassembly [252].
The second possibility is also likely, because a recent study from our laboratory
observed signaling from the early endosomes [266]. Even when the EGFR are
accumulated in the early endosomes, the receptors are able to emit signals and activate
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the downstream effectors. This study also supports our observation of chronic arsenite
exposure-induced overexpression of EGFR and strong EGFR activation at 60 minutes
post-stimulation by EGF (Fig. 7, Fig. 12). Because previous studies have observed
increased levels of proteins that are involved in recycling, the third possibility is highly
likely as well, as we observed a similar results in our RT-qPCR data (Fig. 9). Overall, in
response to chronic arsenite exposure, the route of EGFR trafficking was altered, and
they were aggregated, which was significantly different from the untreated Beas-2B
cells. However, further studies need to be performed to draw conclusions.
Another approach to identifying alterations in the endocytic trafficking of EGFR
was to measure the mRNA levels of the ErbB family receptors as well as their ligands.
We performed RT-qPCR and observed a significant increase in mRNA level of TGFα.
The increase in TGFα was observed in an exposure time-dependent manner (Fig. 9).
Though the actual protein level of TGFα is still yet to be measured, our data suggest that
in response to chronic arsenite exposure, the cells try to make more of the ligand that is
associated with the recycling of the EGFR, due to possible decreased cell surface
expression of the EGFR. Though it may not be the predominant mechanism to chronic
arsenite carcinogenicity, it is likely that an increase in TGFα mRNA levels will contribute
to arsenite carcinogenicity, as increase in TGFα mRNA levels have shown to accelerate
cell proliferation [248, 267].
To determine if there are any alterations in sensitivity to AG1478 in arsenitetreated Beas-2B cells, we performed Alamar Blue assay and measured the cell viability
in response to different concentrations of AG1478. Because 24-weeks arsenite treated
cells stimulated overexpression of EGFR, we expected the cells to have higher
sensitivity to AG1478, as Schiff et al. have shown increased sensitivity to getfitnib in
thyroid cancer cells that overexpress EGFR [149]. However, we observed a comparable
trend of cell viability between 24-weeks arsenite treated cells and the untreated cells
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(Fig. 11). Further studies are needed to make a concrete conclusion on their sensitivity
to tyrosine kinase inhibitor.
Because Andrew et al. observed prevention of EGFR degradation in response to
acute high levels of arsenite treatment [119], we investigated whether chronic exposure
of “a physiologically relevant” level of arsenite treatment prevents the EGFR degradation
in a similar manner. Under normal physiological conditions, EGF-induced EGFR
activation increases significantly within 5 minutes, and diminishes within an hour.
Although we did not observe a clear decrease in the EGFR degradation in response to
chronic arsenite treatment, the overall protein expression levels of the EGFR and activity
in the arsenite-treated cells were stronger than the untreated cells (Fig. 12). This
incomplete EGFR degradation suggests we will need to select longer time points for
EGF treatment to observe a nearly complete degradation of EGFR. The present work is
summarized in a schematic diagram in Figure 13.
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Figure 13. The schematic diagram of the possible mechanisms of chronic
arsenite-induced carcinogenesis. Chronic exposure of “a physiologically relevant”
level of arsenite alters the endocytic trafficking of EGFR via constitutive recycling of the
internalized EGFR, leading to overexpression of EGFR on the surface of the cell.
Another possible mechanism of chronic arsenite-induced overexpression of EGFR is
chronic arsenite-induced increase in induction of TGFα synthesis.
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CHAPTER 5
FUTURE STUDIES
This thesis contributes in identifying novel roles and targets of chronic arsenite
exposure. To determine whether chronic exposure to “a physiologically relevant” level of
arsenite alter the EGFR endocytic trafficking pathway, we performed
immunofluorescence. We observed altered EGFR distribution in cells that were grown in
arsenite for 24 weeks, as compared to the untreated cells, but we were not able to
conclude the exact location of the EGFR. To understand the underlying mechanism
behind this phenomenon, the EGFR co-localization with other organelles, such as the
ER and Golgi apparatus, or with other endocytic compartment, such as the early
endosomes, will be needed to identify which step(s) of the EGFR endocytic trafficking
are being inhibited by chronic arsenite exposure.
In order to draw conclusions from RT-qPCR analysis, we would need to analyze
other ErbB family receptors and their ligands, and repeat the experiments with other
human bronchial epithelial cell lines, such as HBEC. We observed a significant increase
in TGFα mRNA levels in an exposure time-dependent manner. After we determine a
consistent increase in the protein expression level of TGFα and cell surface EGFR
localization, we will knockout TGFα by transfection of its shRNA to the cells and observe
its phenotypes, such as proliferation efficiency and anchorage-independent growth, to
determine contribution of increased level of TGFα in arsenite-induced carcinogenicity. If
we do not observe a consistent increase in TGFα protein expression level and observe
less cell surface EGFR localization, it is possible that chronic arsenite-treated cells may
be upregulating TGFα mRNA level to bring the EGFR to the plasma membrane due to
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chronic arsenite-induced accumulation of EGFR in the endocytic compartments. If this
were the case, we will introduce exogenous TGFα to the chronic arsenite-treated cells
and determine if TGFα mRNA level is still being induced. Once this has been completed,
we will then be able to determine the significance of TGFα role in an arsenite-induced
carcinogenesis. An inconsistent changes in the protein levels of TGFα can be explained
by chronic arsenite exposure affecting the expression of proteins that control ligand
processing and ligand:receptor down-regulation. By analyzing expression levels of
proteins involved in ligand processing, such as ADAMs (A Disintegrin And
Metalloproteinase) [268], we will be able to refine our model and identify appropriate
molecular mechanisms. Also, it is possible that TGFα mRNA level is not consistent with
the protein level due to non-coding RNA, such as miRNA, thus we will investigate
miRNA that are involved in TGFα regulation. Partial complementarity between miRNA
and the target mRNA can decrease protein expression level without decreasing the
mRNA level. It should be noted that there was no observed change in EGFR mRNA
level in response to chronic arsenite exposure. This phenomenon can be due to 1)
arsenite-induced increased translation of EGFR, 2) arsenite-induced decreased EGFR
degradation, or 3) combination of both mechanisms. To elucidate whether arseniteinduced overexpression of EGFR is due to prevention of EGFR degradation, we will
perform immunoblot analysis using cyclohexamide to measure EGFR degradation
efficiency in response to chronic arsenic exposure.
Furthermore, as mentioned earlier, the interplay between clathrin-mediated
endocytosis and caveolin-mediated endocytosis controls the expression of EGFR in the
cells to prevent overstimulation, as caveolin-mediated endocytosis preferentially couples
to EGFR degradation [251]. In our study, we observe overexpression of EGFR in
response to chronic arsenite exposure, this suggests a possible role of arsenite in
dysregulating the interplay between the two distinct endocytic trafficking pathways,
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contributing to arsenite-induced carcinogenesis by allowing overstimulation of the EGFR
signaling. Ironically, however, an earlier study showed sub-chronic high levels of
arsenite increases caveolin protein expression level in liver sinusoidal endothelial cells
[269]. If we observe increase in caveolin levels in cells treated with low levels of chronic
arsenite exposure, we will, then, use chloroquine (CHQ), lysosomal inhibitor, to assess
relationship between caveolin expression and chronic arsenite-induced EGFR
overexpression. If we observe a greater EGFR overexpression in cells that are cotreated with arsenite and CHQ, as compared to cells with arsenite treatment only, this
will suggest chronic arsenite-induced caveolin-mediated endocytosed EGFR are being
degraded via lysosomes, suggesting chronic arsenite does not cause accumulation of
the EGFR in the cells by disrupting the interplay between the two distinct endocytic
trafficking pathways. Alternatively, if we observe comparable levels of the EGFR
expression with CHQ, as compared to the cells with arsenite treatment only, this
suggests caveolin-mediated endocytosed EGFR are not being degraded via lysosomes,
and this could further lead to a possible perturbed degradation pathway.
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